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Abstract
Background: Hypercortisolemia has been suggested as a primary hormonal mediator of whole-body catabolism following
severe burn injury. Ketoconazole, an anti-fungal agent, inhibits cortisol synthesis. We, therefore, studied the effect of
ketoconazole on post-burn cortisol levels and the hyper-catabolic response in a prospective randomized trial (block
randomization 2:1).
Methodology/Principal Findings: Fifty-five severely burned pediatric patients with .30% total body surface area (TBSA)
burns were enrolled in this trial. Patients were randomized to receive standard care plus either placebo (controls, n=38) or
ketoconazole (n=23). Demographics, clinical data, serum hormone levels, serum cytokine expression profiles, organ
function, hypermetabolism measures, muscle protein synthesis, incidence of wound infection sepsis, and body composition
were obtained throughout the acute hospital course. Statistical analysis was performed using Fisher’s exact test, Student’s t-
test, and parametric and non-parametric two-way repeated measures analysis of variance where applicable. Patients were
similar in demographics, age, and TBSA burned. Ketoconazole effectively blocked cortisol production, as indicated by
normalization of the 8-fold elevation in urine cortisol levels [F(1, 376)=85.34, p,.001] with the initiation of treatment.
However, there were no significant differences in the inflammatory response, acute-phase proteins, body composition,
muscle protein breakdown or synthesis, or organ function between groups.
Conclusions: Both groups were markedly hypermetabolic and catabolic throughout the acute hospital stay. Normalization
of hypercortisolemia with ketoconazole therapy had no effect on whole-body catabolism or the post-burn inflammatory or
hypermetabolic response, suggesting that hypercortisolemia does not play a central role in the post-burn hypermetabolic
catabolic response.
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Introduction
The hypermetabolic response to a severe burn, defined as a
burn encompassing greater than 40% of the total body surface
area (TBSA), evokes a catabolic state that persists long after the
initial insult [1]. This response is characterized by futile substrate
cycling, increased oxygen consumption, glycogenolysis, proteoly-
sis, and lipolysis [1–3]. The primary mediators of this deleterious
response have been thought to be endogenous catecholamines and
cortisol [1,4]. Urine cortisol levels are elevated 7–10 fold after
severe burn and remain elevated beyond the acute phase [4,5].
Hypercortisolemia is associated with whole-body catabolism,
inflammation, and immune dysfunction [4,6–8]. Under normal
conditions, there is a negative feedback loop in the hypothalamus-
pituitary-adrenal (HPA) axis. After severe stress, the HPA axis’ role
is to maintain hemodynamic stability and physiologic homeostasis
by controlling the release of acute-phase proteins. In response to
severe physiologic stress, corticotrophin-releasing factor and
arginine vasopressin, which are synthesized in the hypothalamus,
activate circulating adrenocorticotropic hormone (ACTH). ACTH
induces the synthesis of cortisol from the adrenal cortex. Increased
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the release of ACTH [9]. After severe burn injury, the negative
feedback loop between cortisol and ACTH is deranged [10]. This
physiologic, metabolic disruption leads to persistent elevations in
cortisol in severely burned pediatric patients.
Ketoconazole is an imidazole anti-fungal agent that has been
shown to diminish steroid synthesis by blocking P450-dependent
enzyme systems [11,12]. It has been shown to be effective in
reducing both stimulated and basal cortisol secretion in both
normal and Cushing’s (hypercortisolemic) patients [13,14]. Keto-
conazole also reduces the incidence of acute respiratory distress
syndrome (ARDS) in critically ill patients and shortens length of
ICU stay [15]. Preliminary studies in adult burn patients have
shown that urinary cortisol excretion is decreased after one week
of ketoconazole administration [8]. Although patients do not have
completely normal urinary cortisol excretion, they have reduced
muscle protein turnover and improved muscle protein balance [8].
The effect of ketoconazole administration on immune function,
organ function, or hormonal balance has not been fully
investigated in this patient population. Moreover, to our knowl-
edge, the effect of inhibiting excess cortisol production has not
been evaluated in the pediatric burn population. We hypothesized
that the administration of ketoconazole to block excess cortisol
production in severely burned pediatric patients during the acute
hospitalization would attenuate inflammation, hypermetabolism,
and protein wasting.
Results
Demographics
Two-thousand eight-hundred twenty-one patients were assessed
for eligibility to be enrolled in our research studies. We enrolled
516 patients (Fig. 1, Consort Diagram), 455 of whom were
enrolled in studies of other anti-catabolic agents. Of the 38
patients allocated to placebo, 6 were excluded because they
received anti-catabolic agents, leaving 32 patients in the standard
of care/placebo group. Of the 23 patients randomized to
ketoconazole, 6 were excluded. One patient did not receive the
drug, while 5 were given drug under non-optimal conditions,
leaving 17 patients that received standard of care plus ketocona-
zole treatment [per os (p.o.) on an acidic stomach] in the treatment
group. There were no differences in age, gender, length of ICU
stay, burn size, third-degree burn, length of ICU stay per percent
burn, number of required operations, or time between operations
between groups (Table 1). Incidence of inhalation injury was
comparable in both groups (Table 1). Ketoconazole administra-
tion did not decrease the incidence of pneumonia, sepsis, or multi-
organ failure (MOF) (Table 1).
Cytokines, Hormones, and Proteins
Urinary cortisol was increased 8 fold after severe burn injury
(Fig. 1). Ketoconazole treatment decreased urinary cortisol
excretion to normal levels [F(1, 376)=85.34, p,.001]. This effect
was evident by post-burn day 8 [F(7, 376)=8.21, p,.001] (Fig. 2).
Catecholamine levels were significantly elevated after severe burn.
Ketoconazole treatment had no effect on urine catecholamine
levels [F (1, 329)=1.08, p=.30] (norepinephrine shown in Fig. 3).
Confirming previous studies, we found that severe burn injury
induced a vast inflammatory response. Ketoconazole did not alter
any of the 17 serum cytokines measured (not shown). Serum acute-
phase proteins were physiologically deranged throughout the acute
hospitalization, but were not different based on treatment group.
There were no differences in serum IGF-1, IGFBP-3, or rhGH
between the groups. There were no differences in estrogen, free or
bound testosterone, or free or bound progesterone levels between
the groups. There were no significant or sustained differences in
serum complement C3, a2-macroglobulin, haptoglobin, or C-
reactive protein. Ketoconazole had no effect on triglycerides or
free fatty acids.
Adrenocorticotropic hormone (ACTH or Cosyntropin) chal-
lenge tests showed no differences in responses in either patient
group (Table 2). Both treatment groups were adrenally competent
and responded to the challenge according to established guidelines
[16].
Indirect Calorimetry
As previously reported, burn injury increases resting energy
expenditure (REE), indicating a vast hypermetabolic response. In
this study, control patients demonstrated a decrease in REE, as
predicted by the Harris-Benedict equation, from 14867%
predicted at admission to 13967% predicted at discharge (delta
29% REE) (Fig. 4a). Ketoconazole-treated patients exhibited an
increase in predicted REE from 143611% at admission (before
treatment) to 144611%, although this was not statistically
significant (delta +1% REE), indicating that ketoconazole treat-
ment had no effect on REE from admission to discharge when
compared to controls.
Muscle Protein Synthesis
Stable isotope infusion studies were used to measure muscle
protein synthesis and breakdown to determine net protein balance.
Burned children had a negative net protein balance in skeletal
muscle at the time of the first study, at one week post admission.
Peripheral muscle catabolism further increased towards the second
study, which was conducted around 3–4 weeks post admission.
There were no differences between control and ketoconazole for
net protein balance, protein synthesis, or the fractional synthetic
rate of muscle protein synthesis (Fig. 4b).
Body Composition
Severe burn causes marked changes in body composition during
acute hospitalization. Both control and ketoconazole patients
experienced a 1% loss in lean body mass (LBM) during the study
period. Control patients lost 2% of bone mineral density (BMD)
and 4% of bone mineral content (BMC), while ketoconazole-
treated patients lost 4% of their BMD and 8% of BMC (Fig. 3c).
Control patients experienced 6% gains in whole-body fat, though
this was not significantly different than the 9% gains in whole-
body fat experienced by drug-treated patients (Fig. 3c).
Organ Function
In the control group, liver size markedly increased after injury.
Ketoconazole did not attenuate this increase in liver size
compared to the control treatment (data not shown).
Predicted cardiac output (CO), cardiac index (CI), predicted
heart rate (HR), predicted stroke volume (SV), and cardiac work
were altered in burn patients. Ejection fraction (EF) was preserved
in severely burned pediatric patients. Ketoconazole had no effect
on predicted CO, CI, predicted HR, or predicted SV. Ketoco-
nazole treatment had no effect on cardiac function (data not
shown).
We further examined serum markers of organ function and
homeostasis. We found that burn increased creatinine, BUN, and
total bilirubin levels, while burn was associated with decreased
total protein levels. Ketoconazole treatment did not have any
effect on liver or renal function compared to the control treatment
(data not shown).
Ketoconazole Post-Burn
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Major thermal injury is followed by a profound catabolic
response that persists for years after injury [1]. This catabolic state
after injury leads to increased risk for infection, severe muscle
wasting, morbidity, and mortality. The response has been thought
to be mediated by increased plasma catecholamines, glucagon,
and cortisol [4]. If left unabated, patients can have severe cardiac
stress, insulin resistance, and persistent derangements in structure
and function of vital organs [1,4,17]. It has been postulated that
excess cortisol, compounded by prolonged muscular inactivity,
increases skeletal muscle protein breakdown in this patient
population [18–21]. This study was designed to reveal whether
ketoconazole treatment attenuates the hypercatabolic and inflam-
matory response to severe burn trauma by decreasing cortisol
synthesis. The principal findings in this study were that
ketoconazole successfully decreased the excretion of urinary
cortisol. However, it did not improve the hypermetabolic or
catabolic condition of the patient population studied.
Ketoconazole blocks the 14-demethylation of lanosterol, thus
preventing its conversion to cholesterol [12,22]. It has been shown
to block steroid production and cortisol production [12]. Based on
the results of this study, it may be incorrect to say that
ketoconazole blocks steroid production, but rather, it interferes
with steroid synthesis [23]. Forty-nine patients were included in
this study, with 17 receiving ketoconazole enterally at a dose of
5 mg/kg every 12 h. These 17 patients had a significant decrease
in urinary cortisol excretion with ketoconazole treatment when
compared to controls. Serum cortisol levels were not affected by
ketoconazole treatment (data not shown). Of note, the normal
circadian rhythm for serum cortisol is physiologically deranged
and lost after severe burn injury, making serum cortisol an
inaccurate measure of the total daily production of cortisol in our
patients [24,25]. Instead, we measured urine cortisol, a more
reliable measurement of the HPA axis in our patient population
[26]. There were no significant differences in the patient
demographics in the two arms of the study. Adrenal function
was assessed in all patients involved in the study by ACTH
challenge tests. None of the patients in this study had clinical signs
or symptoms of adrenal insufficiency (no response to ACTH
challenge tests). Hypercortisolemia has been shown to contribute
to reduced T-helper lymphocyte proliferation and immunocom-
petence [27]. Here, patients receiving ketoconazole did not have a
lower incidence of minor infections (p..05). In addition, though
ketoconazole is an anti-fungal agent, there were no significant
differences in the numbers of patients with sepsis or MOF.
Ketoconazole treatment did not decrease REE and thus,
hypermetabolism. Both patient populations had REE that was
significantly higher than normal values throughout the study
period. Excess cortisol has been linked to increases in REE [5,18].
In this study, muscle protein catabolism was elevated in control
burn patients (237657 nmol/100 ml leg/min). In the ketocona-
zole-treated burn patients, cortisol was reduced to normal levels,
but muscle protein catabolism remained elevated (236654 nmol/
100 ml leg/min). Muscle protein synthesis is also elevated in burn
patients to compensate for the increased catabolism, but the net
Assessed for eligibility 
2000-2010 (n=  2821)
Allocated to Control (n=38)
• Received allocated intervention (n=32)
￿ Received anti-catabolic agent (n=6)
Allocated to Ketoconazole (n=23)
￿ Received allocated intervention (n=22)
￿ Did not receive allocated intervention (n=1)
Lost to follow up (n=0)
Discontinued intervention (n=0)
Lost to follow up (n=0)
Discontinued intervention (n=0)
Analyzed (n=32)
￿ Excluded from analysis (n= 0)
Analyzed (n=17)
￿ Excluded from analysis (n=5) – did not 
receive drug on an acidic stomach.
Enrollment criteria not met (n=  2305)
Patients Enrolled 
(516)
Randomized to other trials (455)
Figure 1. Consort Diagram.
doi:10.1371/journal.pone.0035465.g001
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treatment (259641 vs.224623 nmol/100 ml leg/min, p=.57).
The data suggest that the increase in muscle catabolism seen with
severe burn injury is not mediated by elevated cortisol levels.
Table 1. Patient demographics and the effect of ketoconazole.
Control (n=32) Ketoconazole (n=17) p,.05 p value
Length of ketoconazole administration (days) NA 3468* S ,.001
Demographics
Age (yrs) 9617 61 NS .35
Gender (F/M) 11/21 3/14 NS .22
XHispanic (%) 94 76 NS .16
Caucasian (%) 6 24 NS .16
Time to admission (days) 4614 61 NS .65
LOS ICU survivors (days) 35644 0 67 NS .48
TBSA burned (%) 57636 3 66 NS .19
3rd degree (%) 49655 3 68 NS .74
Flame burn (%) 92 73 NS .97
Electrical burn (%) 4 9 NS .97
Scald burn (%) 4 18 NS .97
LOS/% TBSA burned survivors (days/%) 0.660.06 0.660.09 NS .94
No. of surgeries in survivors 5615 61 NS .68
Inhalation injury (%) 13 (41%) 9 (53%) NS .41
Infections, Sepsis
Number of minor infections 10 (31%) 5 (29%) NS 1.0
Sepsis (n) 5 (16%) 3 (17%) NS 1.0
Multi-organ failure (n) 7 (22%) 5 (29%) NS .72
TBSA = total body surface area. LOS = length of stay. Data are presented as means 6 SEM, counts, or percentages. *Significant difference for control versus
ketoconazole for corresponding parameter, p,.05.
doi:10.1371/journal.pone.0035465.t001
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Figure 2. Ketoconazole administration reduces urinary cortisol
levels. Data are presented as mean 6 SEM. *Significant difference for
control vs. ketoconazole at corresponding time point, p,.05. There
were no significant differences between control and ketoconazole-
treated patients before ketoconazole treatment. Ketoconazole therapy
was initiated by the first week post burn. Urinary cortisol approached
normal values in ketoconazole-treated patients and was significantly
decreased during therapy.
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Figure 3. Nor-epinephrine levels are not altered by ketocona-
zole administration. Data are presented as mean 6 SEM. Norepi-
nephrine was significantly elevated post-burn compared to normal
values (p,0.05).
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between groups. Immobility confounded by hypermetabolism and
the increased catabolic state led to losses in BMC and BMD.
While excess cortisol has been linked to short-term bone loss [28],
there were no gains in BMC or density despite ketoconazole
treatment.
Severe burn injury induced a profound hyper-inflammatory
response. Pro-inflammatory cytokines and acute-phase proteins
were elevated throughout the study period. Ketoconazole treat-
ment did not attenuate the inflammatory response post burn.
Ketoconazole has been used to block androgen steroid synthesis in
prostate cancer and been shown to cause gynecomastia in male
patients in other studies [29,30]. Ketoconazole treatment did not
cause gynecomastia in these patients and did not inhibit androgen
steroid synthesis, despite blocking steroid synthesis and cortisol.
Ketoconazole had no effect on liver function, size, or weight
Table 2. ACTH stimulation test results.
Time of measurements Control
Mean increase from
baseline Ketoconazole
Mean increase from
baseline p value
Baseline 2366 2 38616 2 .31
30 minutes 36661 3 634 9 624 2569 .23
60 minutes 56633 2 637 9 628 2664 .26
Data are presented as means 6 SEM. There were no significant differences between groups at baseline, 30 min, or 60 min and no differences in mean increases.
doi:10.1371/journal.pone.0035465.t002
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function. Renal function measures did not differ between standard
of care and standard of care with ketoconazole treatment.
Preliminary studies have shown an improvement in muscle
protein synthesis with 7 days of ketoconazole treatment in adults
[8]; however, this was not duplicated in this study, possibly due to
the size of the burn studied, the pediatric population studied, or
the dose of ketoconazole treatment used. Twenty-four-hour
urinary cortisol in excess of 300 mcg/day is diagnostic of
Cushing’s Syndrome [31]. Our patients have values that approach
these levels and remain elevated long after the acute hospitaliza-
tion [5]. Hypercortisolemia leads to profound muscle wasting and
growth retardation [31]. Even after successful definitive pituitary
surgery, patients with Cushing’s Syndrome have no significant
improvement in fat mass or LBM [32]. Furthermore, urine cortisol
levels return to normal levels without therapy at 3 months post
burn, while muscle catabolism persists up to 9 months after injury
[1,5]. Despite reversing hypercortisolemia acutely in severe burned
pediatric patients, catabolism was not reversed or attenuated.
These data indicate another cause for continued muscle proteol-
ysis.
Conclusions
The data suggest that cortisol may not be the predominant
mediator of the hypermetabolic, hypercatabolic response to severe
burn injury. The effects of and elevations in catecholamines and
cortisol persist well into the rehabilitative period–months to years
after injury [1,4,17]. Significant gains in LBM, muscle protein
synthesis, and multi-organ dysfunction have been achieved by
blocking the effects of plasma catecholamines [17,33–35]. This
study attempted to isolate the potential benefits of interrupting
excess cortisol in severely burned children. We have shown that
attenuating cortisol levels by decreasing newly synthesized cortisol
during hospitalization after the initiation of the hypermetabolic
response did not diminish inflammation and hypermetabolism or
alter morbidity and mortality. We conclude that efforts to abate
the hypermetabolic, hypercatabolic response to stress must not
exclusively address hypercortisolemia, but must inhibit the effects
of catecholamines or other factors such as glucagon, either jointly
or solely.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics Statement
This study was reviewed and approved by the Institutional
Review Board of the University of Texas Medical Branch,
Galveston, Texas. Prior to the study, each subject, parent, or
child’s legal guardian signed a written informed consent form. All
thermally-injured children had burns over 30% of their TBSA,
were admitted and consented to the study protocol between 2000
and 2008, and required at least one surgical intervention. After the
patient or their parent or legal guardian consented to the study,
the subjects were randomized to receive ketoconazole or placebo.
Ketoconazole was given enterally at a dose of 5 mg/kg every 12 h
on an acidic stomach and was administered throughout the initial
acute hospitalization.
Participants
There were 38 patients randomized to control (standard of care)
and 23 randomized to ketoconazole. Of the patients randomized
to standard of care alone, six were excluded because they received
anti-catabolic agents. Of the patients randomized to receive
ketoconazole, one did not receive the drug and five patients did
not receive the drug on an acidic stomach. Data from 49 severely
burned patients were analyzed in this study (32 Control and 17
Ketoconazole) (Fig. 1).
Within 24 h of admission, all patients underwent total burn
wound excision. Wounds were covered with 4:1 expanded
autograft or homograft [4]. After the first operative procedure, it
took 5–10 days until the donor site healed and patients returned to
the operating room. This approach was continued until all wound
areas were covered with autologous skin material. Nutritional
treatment was the same for all subjects; a caloric daily intake of
1500 kcal/m
2 body surface +1500 kcal/m
2 area was delivered as
previously published [36]. The nutritional route of choice for our
patient population was enteral, using Vivonex TENH.
Patient demographics (age, date of burn and admission, sex,
burn size, and depth of burn) and concomitant injuries such as
inhalation injury, sepsis, morbidity, and mortality were recorded.
Inhalation injury was diagnosed by bronchoscopy along with a
consistent history. Minor infection was defined as a positive culture
with less than 10
5 colony forming units per gram of tissue or
organisms. Wound infection was defined as .10
5 colony forming
units per gram of tissue in a wound biopsy with the identification
of the pathogen. Repeated counts of the same bacteria in the same
location were counted as the same infection. Sepsis and infection
were defined by the American Burn Association and Society of
Critical Care Medicine guidelines [37–39]. MOF was defined as
previously published [4]. Wound healing was evaluated by
necessary time between operative interventions–defined here by
the time needed for donor sites to heal so that further autografting
of the burned patient is possible. Pulmonary function was
evaluated from incidence of ventilation, length of ventilation,
incidence of atelectasis, and ARDS as defined by the ARDS
network [40]. Pneumonia was defined by guidelines recently
published by the American Burn Association [37].
Cytokines, Hormones, and Proteins
Blood and urine were collected from each burn patient at
admission, preoperatively, and 5 days postoperatively for 4 weeks
and were used for analysis of serum hormone, protein, cytokine,
and urine hormones. Blood was drawn in a serum-separator
collection tube and centrifuged for 10 min at 1320 rpm; the serum
was removed and stored at 270uC until assayed. Serum hormones
and acute-phase proteins were quantified using HPLC, nephe-
lometry (BNII, Plasma Protein Analyzer Siemens Healthcare
Diagnostics, West Sacramento, CA), and ELISA techniques [4].
The Bio-Plex Human Cytokine 17-Plex panel was used with the
Bio-Plex Suspension Array System (Bio-Rad, Hercules, CA) to
profile expression of 17 inflammatory mediators [41].
Cosyntropin challenge tests were performed using a high
performance liquid chromatography (HPLC) method on a
Beckmann Coulter instrument comprising a 508 autosampler,
125 pump system, 168 DAD (diode array detector), and 24 Karate
software. The column was a Symmetry Shield C18 3.5 micron,
4?56150 mm from Waters Corporation. Mobile phase A consisted
of HPLC-grade methanol with 0.1% trifluoroacetic acid (TFA).
Mobile phase B was HPLC-grade water (pH=2) with TFA. An
isocratic method with 18% over 10 min was used. The analytical
range is 0.1 to 10000 ng/ml. Serum samples were extracted on a
HLB 1 cc 30 mg Oasis solid-phase cartridge (Waters Corporation)
by conditioning with 1 ml methanol followed by 1 ml water,
loading 200 ml sample in 800 ml acidified water, washing with 50%
methanol in water (twice), and eluting with methanol (pH=10.7).
Ketoconazole Post-Burn
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air, reconstituted in 50% methanol water (pH=2), and subjected
to HPLC analysis. Patients were fasted at least 8 h prior to the test,
and measurements were taken prior to 10 a.m. A baseline blood
sample was drawn, and samples were subsequently drawn at
30 min and 60 min later to determine a patient’s response.
Hypermetabolism
Indirect calorimetry. All patients underwent REE mea-
surements within one week following hospital admission and
weekly thereafter during their acute hospitalization. All REE
measurements were performed between midnight and 5 a.m. while
the patients were asleep and receiving continuous feeding. REE
was measured using a Sensor-Medics Vmax 29 metabolic cart
(Yorba Linda, CA) as previously published [42]. REE was
calculated from oxygen consumption and carbon dioxide produc-
tion using equations described by Mlcak and colleagues [42].
Measured values were compared to predicted normal values,
based upon the Harris-Benedict equation, and to body mass index
[42].
Muscle protein synthesis. The degree of protein catabolism
was quantified using stable isotope tracers. Protein kinetic studies
were performed beginning between 5:00 and 7:00 a.m. on
postoperative day five after the first excision and grafting
procedure. All stable isotope studies consisted of a 5-h infusion
of
2H5-Phenylalanine. Because phenylalanine is neither synthe-
sized nor degraded in the peripheral tissues (it is metabolized only
in the liver), measurement across the leg reflects the net balance of
protein synthesis and breakdown. Blood samples were taken
simultaneously from an ipsilateral femoral artery and vein for this
determination. Indocyanine green was used to determine leg blood
flow. The blood concentration of unlabeled phenylalanine was
determined by gas chromatography-mass spectrometry using the
internal standard approach and tert-butyldimethylsilyl esters, as
previously described [43]. Indocyanine green concentrations were
determined spectrophotometrically at l=805 nm on a Spectronic
1001 (Bausch and Lomb, Rochester, NY). As phenylalanine is
neither synthesized nor degraded in the periphery, the difference
in concentration of this substrate in the femoral arterial and
venous plasma pools reflects the net balance of leg skeletal muscle
protein synthesis and breakdown. The net balance (NB) was
calculated and standardized for leg volume by the following
equation: NB = (CA 2CV) N BF, where CA and CV are free amino
acid concentrations in blood from the femoral artery and vein and
BF is leg blood flow in cc/min/100 ml leg. Leg blood flow was
determined from a modification of Fick’s equation. BF was
normalized for each patient by leg volume. Subject weight, leg
circumference at prescribed points relative to anatomic landmarks,
and the distances between these points were used to mathemat-
ically model leg volume [43]. Protein synthesis (PS) was calculated
from the formula PS = (EA N CA 2 EV N CV) N BF/EM, where
EA, EV, and EM are the amino acid enrichments in artery, vein,
and muscle, respectively. Protein breakdown (PB) was calculated
from the formula PB = PS 2 NB.
Body composition. Height and body weight were deter-
mined clinically 5 days after admission and at discharge. Total
LBM, fat, BMD, and BMC were measured by dual energy x-ray
absorptiometry (DEXA). A hologic model QDR-4500W DEXA
(Hologic Inc, Waltham, MA) was used to measure body
composition as previously published [44–48].
Organ Function
M-Mode echocardiograms were used to determine CO, CI, SV,
resting HR, and EF. SV and CO were adjusted for body surface
area and expressed as indexes. All cardiac ultrasound measure-
ments were obtained using a Sonosite Titan echocardiogram, with
a 3.5 MHz transducer. Three measurements were performed and
averaged for data analysis. Recordings were performed with
subjects in a supine position and breathing freely, as recommended
by the American Society of Echocardiography [4,45]. Absolute
values were then expressed as percent of normal based on
published nomograms [49].
Liver ultrasound measurements were made with the HP Sonos
100 CF (Hewlett Packard Imaging Systems, Andover, MA). The
liver was scanned using an Eskoline B-scanner, and liver size/
volume was calculated using a previously published formula [50].
Actual size was then compared to predicted size [44]. Serum
proteins, e.g., creatinine, bilirubin, and total protein were
determined using standard nephelometry to evaluate organ
function [4].
Statistics
The distribution of the data was evaluated using QQ plots and
the Kolmogorov-Smirnov normality test. To test for differences in
normally-distributed data (cortisol, catecholamines), we conducted
a two-way repeated measures ANOVA. To test for differences in
non-normally distributed data (cytokines), we used two-way
repeated measures ANOVA on Ranks. In either instance, we
determined group differences using a post-hoc Bonferroni-Dunn
correction to manage multiple comparisons. Two-sided equal-
variance t-tests were used to compare continuous data. Fisher’s
exact test was used for frequency data. P values less than.05 were
considered significant. Continuous data are presented as mean 6
SD or SEM. Frequency data are presented as counts and
percentages. SAS (version 9.2) was used for data analysis and
hypothesis testing. SigmaPlot (version 11.0) was used for graphics.
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